Systematic Review on Efficacy and Safety of Edaravon Dexborneo Combined with Alteplase in the Treatment of Acute Cerebral Infarction
OBJCETIVE:To systematically review the clinical efficacy and safety of edaravon dexborneo combined with alteplase in the treatment of acute cerebral infarction,so as to provide evidence-based support for clinical drug selection.METHODS:PubMed,CBM,CNKI,Wanfang Data and VIP were retrieved to collect the randomized controlled trial(RCT)for clinical efficacy and safety of edaravon dexborneo combined with alteplase(observation group)and alteplase alone(control group)in the treatment of acute cerebral infarction up to Aug.2023.After data extraction and quality evaluation,Meta-analysis was carried out by RevMan 5.3 statistical software.RESULTS:A total of 12 RCT were enrolled,including 1 209 patients.Meta-analysis results showed that,the total effective rate(RR= 1.18,95%CI=1.12-1.23,P<0.000 01),cure rate(RR=1.55,95%CI=1.21-2.00,P=0.000 6)and significant effective rate(RR= 1.27,95%CI= 1.07-1.51,P= 0.006)in the observation group were higher than those in the control group,the National Institutes of Health Stroke Scale score(MD =-2.09,95%CI =-2.84--1.33,P<0.000 01)and inefficiency rate(RR=0.28,95%CI=0.18-0.42,P<0.000 01)were significantly lower than those in the control group,with statistically significant differences.There was no significant difference in the incidence of adverse drug reactions between two groups(RR=1.06,95%CI=0.69-1.61,P=0.80).CONCLUSIONS:Edaravon dexborneo combined with alteplase is clinically more effective and has a comparable safety profile than thrombolysis with alteplase alone in the treatment of acute cerebral infarction.
万方数据
维普
